Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche Submits Total Vitamin D Assay to FDA

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
FDA panel votes to keep indications for Merck, Roche bladder cancer drugs Seeking Alpha - 4/30/2021 7:58:15 AM
FDA panel votes to maintain breast cancer indication for Roche's Tecentriq Seeking Alpha - 4/27/2021 5:26:34 PM
Roche Gets FDA Approval for Cancer-Treatment Test Dow Jones News - 4/23/2021 6:47:00 AM
Roche Q1 sales beats forecast, 2021 outlook confirmed Seeking Alpha - 4/21/2021 5:35:48 AM
Roche Holding beats on revenue; 2021 outlook confirmed Seeking Alpha - 4/21/2021 4:43:18 AM
Roche Backs 2021 Views After 1Q Sales Fall Slightly Dow Jones News - 4/21/2021 1:54:00 AM
Novartis to help produce Roche's Actemra Seeking Alpha - 4/15/2021 5:38:12 AM
Roche’s Evrysdi continues to improve motor function, survival in babies with spinal muscular atrophy Seeking Alpha - 4/15/2021 3:11:36 AM
Novartis Enters Agreement With Roche on Production of the Latter's Drug Dow Jones News - 4/15/2021 2:14:00 AM
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study Dow Jones News - 3/22/2021 2:45:00 AM
Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program Dow Jones News - 3/19/2021 10:49:00 AM
SAE   Tuesday, 12/06/11 12:23:51 PM
Re: None
Post # of 252 


Roche Submits Total Vitamin D Assay to FDA for Clearance on Cobas Immunoassay and Elecsys Analyzers

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated, total vitamin D assay (25-hydroxyvitamin D) for use on Roche's full portfolio of laboratory analyzers.* The Elecsys® vitamin D test can be combined with routine testing on existing Roche immunoassay analyzers and integrated chemistry/immunoassay systems, enabling labs to address the growing demand for vitamin D testing while maximizing their productivity.

"The demand for vitamin D testing is increasing rapidly as global deficiency rates rise and studies show a link between insufficiency and disease states," said Randy Pritchard, vice president of marketing at Roche Diagnostics Corporation. "This new test will give healthcare providers confidence in their patient results and, at the same time, enable labs to integrate vitamin D testing into their existing workflow, to save time and maintain 'lean' operations. Roche currently offers the largest menu available on integrated systems, and the submission of the Vitamin D assay demonstrates our continued commitment to the development of assays that can help improve patient care."

According to the National Institutes of Health Office of Dietary Supplements, the serum concentration of 25(OH)D is the best indicator of vitamin D status. It reflects vitamin D produced cutaneously (D3) and obtained from food and supplements (D2 and D3). The ability of an assay to detect both D2 and D3 forms (total vitamin D) is important for physicians who have patients taking vitamin supplements.

The assay is designed for use on all Roche immunoassay systems for low-, mid- and high-volume testing environments, including the Elecsys 2010, cobas e 411, cobas e 601, cobas e 602 and MODULAR ANALYTICS E170 analyzers. The FDA has a 90-day period after the 510(k) submission for substantive review of the application.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

* This product is not cleared or available for use in the U.S. A 510(k) submission is pending.

All trademarks used or mentioned in this release are protected by law.



For further information, please contact:




Betsy Cox




Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN




(317) 521-3911




betsy.cox@roche.com


SOURCE Roche Diagnostics



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences